Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include always present findings: Global developmental delay, Decreased sweating (hypohidrosis), Recurrent infections, and Elevated circulating hepatic transaminase concentration and others; and very common findings: Type II transferrin isoform profile and Microcephaly. 48 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Digestive system | 8 | Inflammation of the large intestine, Chronic diarrhea, Cholestasis |
COG6 encodes component of oligomeric golgi complex 6 (657 aa). Required for normal Golgi function Highest expression in Pituitary (15.0 TPM) and Cells Cultured fibroblasts (13.1 TPM).
COG6-congenital disorder of glycosylation is caused by mutations in the COG6 gene on chromosome 13.
COG6 is classified as a druggable target with score 0.0.
Genetic testing for COG6 is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 5 always present features, 2 very common features, 15 common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for COG6-congenital disorder of glycosylation.
4 publications have been identified in PubMed for COG6-congenital disorder of glycosylation. Research spans Case Report / Case Series (75%) and Review / Meta-Analysis (25%).
Pakanová Z (2025). [PMID: 41362306](https://pubmed.ncbi.nlm.nih.gov/41362306/). *Hum Mutat*. [Case Report / Case Series]
Guterman S (2025). [PMID: 40213872](https://pubmed.ncbi.nlm.nih.gov/40213872/). *Mol Genet Genomic Med*. [Review / Meta-Analysis]
Zhao P (2025). [PMID: 41437099](https://pubmed.ncbi.nlm.nih.gov/41437099/). *Orphanet J Rare Dis*. [Case Report / Case Series]
Zhang L (2024). [PMID: 39528286](https://pubmed.ncbi.nlm.nih.gov/39528286/). *Zhonghua Yi Xue Yi Chuan Xue Za Zhi*. [Case Report / Case Series]
Data assembled from 7 of 12 sources · Last updated Sep 21, 2026, 2:32 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about COG6-congenital disorder of glycosylation
Brain and nerves | 6 | Seizure, Hydrocephalus, Intellectual disability |
Blood and immune system | 5 | Abnormal bleeding tendency (abnormal bleeding), Recurrent infections, Enlarged spleen (splenomegaly) |
Lab test results | 4 | Elevated creatine kinase (muscle enzyme) (elevated circulating creatine kinase concentration), Elevated circulating alkaline phosphatase concentration, Elevated circulating hepatic transaminase concentration |
Muscles | 4 | Generalized hypotonia, Damage to the optic nerve (optic atrophy), Shrinkage of the cerebellum (cerebellar atrophy) |
Kidneys and urinary system | 3 | Unilateral renal agenesis, Hyperechogenic kidneys, Proximal tubulopathy |
Skin | 3 | Dry skin, Decreased sweating (hypohidrosis), Thickened, rough skin (hyperkeratosis) |
Growth and development | 3 | Failure to thrive, Intrauterine growth retardation, Growth delay |
Heart and blood vessels | 2 | Ventricular septal defect, Atrial septal defect |
Head and neck | 1 | Microcephaly |
Eyes | 1 | Damage to the optic nerve (optic atrophy) |
Age of onset: newborn period, before birth, at birth.